One-step customized transurethral resection of the prostate and permanent implant brachytherapy for selected prostate cancer patients: Technically feasible but too toxic - Abstract

Department of Radiotherapy, Institut Curie, 26 rue d’Ulm, Paris, France.

Patients with prominent median lobe hyperplasia and/or high International Prostate Symptom Score (IPSS) are often contraindicated for prostate brachytherapy, mainly because of the risk of post-implant urinary retention. We evaluated an approach combining in the same operative step a limited transurethral resection (TURP) of the median lobe, immediately followed by permanent implant-free seed brachytherapy.

From January 2007 to November 2008, 22 patients underwent a customized limited TURP of their median lobe immediately before brachytherapy. All patients fulfilled our criteria for permanent implant brachytherapy, but presented with a more or less prominent median lobe and/or a high IPSS.

The procedure appeared to be technically feasible, with only 0.3% of migrating seeds, a mean post-implant D90 of 173.4 Gy and a mean post-implant V100 of 96.6%. However, 5 patients (23%) experienced a urinary retention, with two patients having to undergo a complementary post-implant TURP. Moreover, urinary toxicity was more pronounced than in our current experience, with high IPSS at 2 months (mean 19.2) and 6 months (mean 15.8).

Although technically feasible, with relatively few migrating seeds and satisfactory post-implant dosimetric parameters, one-step TURP and brachytherapy was found to be poorly tolerated, with higher than usual urinary retention and urinary toxicity rates. Considering those results, our group is presently evaluating a two-step procedure, with a customized TURP followed after 4-6 months by brachytherapy.

Written by:
Cosset JM, Barret E, Castro-Pena P, Cathelineau X, Galiano M, Rozet F, Pierrat N, Timbert M, Vallancien G.   Are you the author?

Reference: Brachytherapy. 2011 Jan-Feb;10(1):29-34.
doi: 10.1016/j.brachy.2010.11.005

PubMed Abstract
PMID: 21251622 Prostate Cancer Section